Comment on "Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma"

被引：1

作者：

Lin, Jiong ^{[1
]}

机构：

[1] Guangdong Med Univ, Affiliated Hosp, Dept Oncol, 27 South Ren Min Rd, Zhanjiang 524200, Guangdong, Peoples R China

来源：

INVESTIGATIONAL NEW DRUGS | 2021年 / 39卷 / 05期

关键词：

Quisinostat; Esophageal squamous cell carcinoma; Invasion;

D O I：

10.1007/s10637-021-01124-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recently, we read a paper "Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma" published in Investigational New Drugs. Quisinostat may be a promising drug candidate for the treatment of esophageal squamous cell carcinoma. However, some problems existing in the methods part of this paper are worthy of comment.

引用

页码：1454 / 1455

页数：2